Nitrofurantoin Suspension
NDC Package 70954-496-10
Package Information
Nitrofurantoin suspension is nitrofurantoin is indicated in adults and pediatric patients 1 month of age and older for the treatment of urinary tract infections due to susceptible strains of Escherichia coli, Enterococcus species, Staphylococcus aureus, Klebsiella species and Enterobacter species.Limitations of UseNitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses [see Warnings and Precautions (5.7)].Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin and other antibacterial drugs, nitrofurantoin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This formulation utilizes a suspension delivery system. Marketed by Ani Pharmaceuticals, Inc., this product is identified by NDC 70954-496 and is authorized under FDA application ANDA216385.
Identification & Billing
- RxCUI: 311989 - nitrofurantoin 25 MG in 5 mL Oral Suspension
- RxCUI: 311989 - nitrofurantoin 5 MG/ML Oral Suspension
- RxCUI: 311989 - nitrofurantoin 25 MG per 5 ML Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70954 - Ani Pharmaceuticals, Inc.
- 70954-496 - Nitrofurantoin
- 70954-496-10 - 230 mL in 1 BOTTLE
- 70954-496 - Nitrofurantoin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70954-496-10 identifies a specific commercial package of 230 ml in 1 bottle of Nitrofurantoin, a human prescription drug labeled by Ani Pharmaceuticals, Inc.. This suspension is formulated for oral use and contains nitrofurantoin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Ani Pharmaceuticals, Inc. on April 17, 2023. The current certification is valid through December 31, 2027.
How is this Ani Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70954049610. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 230 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.